Oncolytics Biotech Inc. (TSX:ONC)
Canada · Delayed Price · Currency is CAD 1.420
+0.030 (2.16%)
Inactive · Last trade price on Aug 22, 2025
Oncolytics Biotech Employees
Oncolytics Biotech had 28 employees as of December 31, 2024. The number of employees decreased by 1 or -3.45% compared to the previous year.
Employees
28
Change
-1
Growth
-3.45%
Revenue / Employee
n/a
Profits / Employee
-1.09M CAD
Market Cap
142.51M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 28 | -1 | -3.45% |
| Dec 31, 2022 | 29 | 3 | 11.54% |
| Dec 31, 2021 | 26 | 1 | 4.00% |
| Dec 31, 2020 | 25 | - | - |
Oncolytics Biotech News
- 5 days ago - Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep's Potential Across Gastrointestinal Tumors - GlobeNewsWire
- 23 days ago - Penny Stock Oncolytics Biotech Says Colorecatal Cancer Drug's Durability Tops Historical Benchmarks - Benzinga
- 23 days ago - Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer - GlobeNewsWire
- 4 weeks ago - Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study - GlobeNewsWire
- 7 weeks ago - Oncolytics Schedules Type C Meeting With FDA For Pelareorep In Anal Cancer - Nasdaq
- 7 weeks ago - Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer - GlobeNewsWire
- 2 months ago - Oncolytics Biotech® Completes Domicile Change to the United States - GlobeNewsWire
- 2 months ago - Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026 - GlobeNewsWire